Guangzhou Bio-gene Technology Co., Ltd is committed to developing next-generation innovative cell therapies, including immune cell and stem cell therapies, for the treatment of hematologic malignancies, solid tumors, autoimmune diseases, and other serious conditions with unmet clinical needs.

We have established multiple cutting-edge technology platforms, including Rapid target screening and validation platform, Clinical-grade lentiviral vector production platform, Rapid autologous CAR-T manufacturing platform, Off-the-shelf (universal) CAR-T platform and In vivo modified CAR-T platform. These platforms significantly reduce the production costs of cell therapies.

Currently, multiple pipeline candidates are in clinical-stage development, demonstrating promising clinical efficacy. We welcome collaboration opportunities with global biopharmaceutical companies, research institutions, and commercial partners in various areas, including but not limited to: co-development, technology transfer, product licensing, and commercialization. By leveraging complementary strengths and shared resources, we aim to create greater societal value and business opportunities.